Dupixent® (dupilumab) Application for Treatment of Chro

Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review

Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Japan , Paris , France General , France , Georged Yancopoulos , , Regeneron Velocimmune Technology , Regeneron Pharmaceuticals Inc , Twitter , Regeneron Genetics Center , Drug Administration , Nasdaq , Exchange Commission , Dupilumab Development Programdupilumab , Euronext , Biologics License Application , Trial Programthe , Velocimmune Technology Regeneron , Chief Scientific Officer George , Development Programdupilumab , Forward Looking Statements , Digital Mediathis , Regeneron Pharmaceuticals , Product Candidates , Private Securities Litigation Reform Act , Statement Regarding Forward Looking ,